The 15-month plan period provides breathing room, but the company must raise equity or generate positive earnings to regain compliance. Monitor quarterly progress reports and any capital raise filings (e.g., follow-on offering, reverse split announcement). The recent S-3 filing suggests a financing event is likely, which could further dilute existing holders.
Price Chart
Executive Summary
Matinas BioPharma received an additional NYSE American deficiency notice for failing Section 1003(a)(ii) (equity below $4M), compounding a prior 1003(a)(iii) deficiency. The exchange accepted the company's compliance plan and granted until October 2, 2027, but stockholders' equity of $3.02M as of March 31, 2026 leaves a thin margin. The S-3 filed 10 days prior signals likely capital raising activity, which itself is dilutive and underscores underlying distress.
Key Facts
- NYSE American notified non-compliance under Section 1003(a)(ii): stockholders' equity of at least $4.0M required, company had $3.022M as of March 31, 2026
- Company also non-compliant under Section 1003(a)(iii) from prior notice (equity < $6.0M threshold)
- Plan to regain compliance accepted by NYSE American, compliance deadline extended to October 2, 2027
- Company has reported losses in five most recent fiscal years; market capitalization only ~$4M
- S-3 (subordinated debt indenture) filed June 16, 2026 suggests pending capital raise attempt
Financial Impact
Stockholders' equity deficiency of $0.98M to $2.98M below thresholds; no revenue/earnings figures provided in this filing
Risk Factors
- Delisting if compliance not achieved by October 2, 2027 or if progress stalls
- Dilution from upcoming capital raise to shore up equity
- Loss of institutional ownership and liquidity if delisting proceedings begin
- Continued operating losses with no clear path to profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-030342 |
| Exhibit: ex99-1.htm | 0001493152-26-030342 |
| Document: 0001493152-26-030342-index-headers.html | 0001493152-26-030342 |
| Document: 0001493152-26-030342-index.html | 0001493152-26-030342 |
| Document: 0001493152-26-030342.txt | 0001493152-26-030342 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 8-K | $2.53 | awaiting T+20 | — | $1.64 (−34.98%) |
Sep 16, 2026 5w ago | 8-K | $0.1630 $0.1613 | ▼ −1.02% | ▼ −2.23% | $1.64 (+909.20%) |
Sep 4, 2026 7w ago | 8-K | $0.1820 $3.01 | ▼ −1553.85% | ▼ −1552.13% | $1.64 (−803.85%) |
Aug 25, 2026 8w ago | 425 | $0.1973 $0.1750 | ▲ +11.30% | ▲ +12.28% | $1.64 (−733.76%) |
Jul 30, 2026 12w ago | 425 | $0.3174 $0.2000 | ▲ +36.99% | ▲ +40.95% | $1.64 (−418.27%) |
Jul 24, 2026 13w ago | 8-K | $0.3320 $0.1965 | ▲ +40.81% | ▲ +44.11% | $1.64 (−395.48%) |
Jul 13, 2026 15w ago | 425 | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.64 (−242.71%) |
Jul 13, 2026 15w ago | 8-K | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.64 (−242.71%) |
Jun 26, 2026 17w ago | 8-K | $0.6640 $0.2414 | ▲ +63.64% | ▲ +63.37% | $1.64 (−147.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers